Loading...
Header Logo
Keywords
Last Name
Institution

Eric Chi Ching Ko MD, PhD

TitleAssociate Professor
InstitutionUniversity of Massachusetts Medical School
DepartmentRadiation Oncology
AddressUniversity of Massachusetts Medical School
55 Lake Ave North
Worcester MA 01605
vCardDownload vCard
    Other Positions
    InstitutionUMMS - School of Medicine
    DepartmentRadiation Oncology


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Ko EC, Vanpouille-Box C, Formenti SC. Analysis of Pathologic Complete Response 10 Weeks After Radiotherapy-A Radiobiological Sin. JAMA Oncol. 2019 Jul 03. PMID: 31268473.
      View in: PubMed
    2. Ko EC, Formenti SC. Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality. Int J Radiat Biol. 2019 07; 95(7):936-939. PMID: 31120369.
      View in: PubMed
    3. Ko EC, Galluzzi L. Radiation unlocks the therapeutic potential of immune checkpoint blockers in lung cancer patients. Oncoimmunology. 2019; 8(8):1606624. PMID: 31413913.
      View in: PubMed
    4. Ko EC, Benjamin KT, Formenti SC. Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):486-493. PMID: 30370347.
      View in: PubMed
    5. Ko E. Eric Ko on Combining Radiation Therapy With Immunotherapy to Treat Non-Small-Cell Lung Cancer. Oncology (Williston Park). 2018 09 15; 32(9):460-2. PMID: 30248167.
      View in: PubMed
    6. Ko EC, Raben D, Formenti SC. The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer. Clin Cancer Res. 2018 12 01; 24(23):5792-5806. PMID: 29945993.
      View in: PubMed
    7. Ko EC, Formenti SC. Radiotherapy and checkpoint inhibitors: a winning new combination? Ther Adv Med Oncol. 2018; 10:1758835918768240. PMID: 29662550.
      View in: PubMed
    8. Valicenti RK, Pugh SL, Trabulsi EJ, Sartor O, Ko EC, Girvigian MR, Rosenthal SA, Shaves ME, Hoffman-Censits JH, Schallenkamp J, Sandler HM. First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy. Int J Radiat Oncol Biol Phys. 2018 03 01; 100(3):695-701. PMID: 29413282.
      View in: PubMed
    9. Wei XX, Ko EC, Ryan CJ. Treatment strategies in low-volume metastatic castration-resistant prostate cancer. Curr Opin Urol. 2017 Nov; 27(6):596-603. PMID: 28786849.
      View in: PubMed
    10. Ko EC, Michaud AL, Valicenti RK. Postoperative Radiation After Radical Prostatectomy. Semin Radiat Oncol. 2017 01; 27(1):50-66. PMID: 27986212.
      View in: PubMed
    11. Chen HM, Ma G, Gildener-Leapman N, Eisenstein S, Coakley BA, Ozao J, Mandeli J, Divino C, Schwartz M, Sung M, Ferris R, Kao J, Wang LH, Pan PY, Ko EC, Chen SH. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy. Clin Cancer Res. 2015 Sep 15; 21(18):4073-4085. PMID: 25922428.
      View in: PubMed
    12. Carpenter TJ, Kann B, Buckstein MH, Ko EC, Bakst RL, Misiukiewicz KJ, Posner MR, Genden EM, Gupta V. Tolerability, toxicity, and temporal implications of transoral robotic surgery (TORS) on adjuvant radiation therapy in carcinoma of the head and neck. Ann Otol Rhinol Laryngol. 2014 Nov; 123(11):791-7. PMID: 24847162.
      View in: PubMed
    13. D'souza G, Carey TE, William WN, Nguyen ML, Ko EC, Riddell J, Pai SI, Gupta V, Walline HM, Lee JJ, Wolf GT, Shin DM, Grandis JR, Ferris RL. Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr. 2014 Apr 15; 65(5):603-10. PMID: 24326607.
      View in: PubMed
    14. Ko EC, Liu JT, Stone NN, Stock RG. Association of early PSA failure time with increased distant metastasis and decreased survival in prostate brachytherapy patients. Radiother Oncol. 2014 Feb; 110(2):261-7. PMID: 24299969.
      View in: PubMed
    15. Fu S, Yang Y, Das TK, Tirtha D, Yen Y, Zhou BS, Zhou MM, Ohlmeyer M, Ko EC, Cagan R, Rosenstein BS, Chen SH, Kao J. ?-H2AX kinetics as a novel approach to high content screening for small molecule radiosensitizers. PLoS One. 2012; 7(6):e38465. PMID: 22768044.
      View in: PubMed
    16. Tong CC, Ko EC, Sung MW, Cesaretti JA, Stock RG, Packer SH, Forsythe K, Genden EM, Schwartz M, Lau KH, Galsky M, Ozao-Choy J, Chen SH, Kao J. Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One. 2012; 7(6):e36979. PMID: 22761653.
      View in: PubMed
    17. Tong CC, Lau KH, Rivera M, Cannan D, Aguirre-Ghiso J, Sikora AG, Gupta V, Forsythe K, Ko EC, Misiukiewicz K, Gurudutt V, Teng MS, Packer SH, Genden EM, Kao J. Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy. Oncol Rep. 2012 May; 27(5):1580-6. PMID: 22322320.
      View in: PubMed
    18. Ko EC, Genden EM, Misiukiewicz K, Som PM, Kostakoglu L, Chen CT, Packer S, Kao J. Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation. Oncol Rep. 2012 Feb; 27(2):467-74. PMID: 22020564.
      View in: PubMed
    19. Fu S, Rivera M, Ko EC, Sikora AG, Chen CT, Vu HL, Cannan D, Eisenstein S, Rosenstein BS, Aguirre-Ghiso J, Chen SH, Kao J. Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 as a Novel Approach to Enhance Radiotherapy. J Cell Sci Ther. 2011 Oct 13; 1(2). PMID: 23483082.
      View in: PubMed
    20. Ko EC, Stone NN, Stock RG. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):600-7. PMID: 21985944.
      View in: PubMed
    21. Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol. 2011 Jan; 77(1):12-9. PMID: 20304669.
      View in: PubMed
    22. Ko EC, Koprowski CD, Dickson-Witmer D, Penman E, Sorensen M, Hanlon AL, Sammons S, Farach A, Strasser J. Partial vs. whole breast irradiation in a community hospital: a retrospective cohort analysis of 200 patients. Brachytherapy. 2010 Jul-Sep; 9(3):248-53. PMID: 20153984.
      View in: PubMed
    23. Ko E, Luo W, Peng L, Wang X, Ferrone S. Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity. Cancer Res. 2007 Aug 15; 67(16):7875-84. PMID: 17699794.
      View in: PubMed
    24. Luo W, Ko E, Hsu JC, Wang X, Ferrone S. Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J Immunol. 2006 May 15; 176(10):6046-54. PMID: 16670313.
      View in: PubMed
    25. Peng L, Ko E, Luo W, Wang X, Shrikant PA, Ferrone S. CD4-dependent potentiation of a high molecular weight-melanoma-associated antigen-specific CTL response elicited in HLA-A2/Kb transgenic mice. J Immunol. 2006 Feb 15; 176(4):2307-15. PMID: 16455987.
      View in: PubMed
    26. Wang X, Ko EC, Peng L, Gillies SD, Ferrone S. Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2. Cancer Res. 2005 Aug 01; 65(15):6976-83. PMID: 16061683.
      View in: PubMed
    27. Luo W, Hsu JC, Tsao CY, Ko E, Wang X, Ferrone S. Differential immunogenicity of two peptides isolated by high molecular weight-melanoma-associated antigen-specific monoclonal antibodies with different affinities. J Immunol. 2005 Jun 01; 174(11):7104-10. PMID: 15905554.
      View in: PubMed
    28. Wang X, Campoli M, Ko E, Luo W, Ferrone S. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies. J Immunol Methods. 2004 Nov; 294(1-2):23-35. PMID: 15604013.
      View in: PubMed
    29. Ko EC, Wang X, Ferrone S. Immunotherapy of malignant diseases. Challenges and strategies. Int Arch Allergy Immunol. 2003 Dec; 132(4):294-309. PMID: 14707461.
      View in: PubMed
    For assistance with using Profiles, please refer to the online tutorials or contact UMMS Help Desk or call 508-856-8643.
    Ko's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description